Cosmo Pharmaceuticals released topline results from two identical Phase III trials (SCALP 1 and SCALP 2) for clascoterone 5% solution in androgenetic alopecia and reported statistically significant target‑area hair‑count improvements versus vehicle. The combined program enrolled 1,465 patients and the company reported a combined 252% relative improvement in TAHC, with SCALP 2 showing a 539% relative improvement versus placebo. Investors reacted with a multiday buying surge that lifted Cosmo’s shares sharply. Cosmo plans conference and peer‑reviewed presentations next year; regulators will expect full datasets and safety analyses to assess broader dermatology indications beyond the drug’s existing acne approval.